Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of CLL requiring treatment~* Refractory or relapsed disease~* Prior treatment with fludarabine~* Male or Female~* \>18 years of age~Exclusion Criteria:~* Treatment with rituximab within 90 days and alemtuzumab or any monoclonal antibody within 6 months.~* Clinically significant cardiac dysfunction or other significant organ dysfunction~Additional eligibility criteria apply that will be reviewed with potential study subjects at the site.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HCD122 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).